格列喹酮系第二代口服磺脲类降糖药,为高活性亲胰岛β细胞剂,与胰岛β细胞膜上的特异性受体结合,可诱导产生适量胰岛素,以降低血糖浓度。口服本品2~2.5小时后达最高血药浓度,很快即被完全吸收。血浆半衰期为1.5小时,代谢完全,其代谢产物不具有降血糖作用,代谢产物绝大部分经胆道消化系统排泄。
2、口服降糖药治疗:口服药宜选用格列喹酮(gliquidone,glurenorm),此药为第2代磺脲类口服降糖药,口服吸收快而完全,并且主要在肝脏代谢形成羟基化和甲基化的代谢产物95%通过胆汁从粪...
基于1719个网页-相关网页
Gliquidone and gliclazide induced a similarly rapid biphasic insulin secretion, reaching the first peak at 10 minutes and the second lower peak at 30 minutes, followed by gradual decline to near the basal values at the third hours.
格列喹酮刺激分泌高峰在加药后10分钟,30分钟时又有一个稍低的第二峰,随后逐渐下降,至3小时后分泌速率约为基础值的1.1—1.2倍。
参考来源 - 格列喹酮对胰岛HIT·2,447,543篇论文数据,部分数据来源于NoteExpress
结论格列喹酮在老年伴有肾脏损害的糖尿病患者有其独特的优势。
Conclusions Based on the available evidence, gliquidone appears specifically applicable to elderly diabetic patients with kidney diseases.
使用光纤药物溶出仪应用两种标准曲线方程时,比较格列喹酮片的溶出度差异。
Comparing the difference of the dissolution of gliquidone tablets by fiber-optic dissolution test system which use two different standard curve equations.
本发明涉及含有微粉化的格列喹酮为活性成份的药物组合物及所述组合物的制备方法。
The invention relates to a pharmaceutical composition taking gliquidone which contains micronization as an active component and a method for preparing the composition.
应用推荐